Myelofibrosis is a progressive myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, cytopenias, and constitutional symptoms. Although ruxolitinib remains the first-line standard of care, most patients eventually discontinue therapy due to resistance or intolerance. Consequently, selecting appropriate second-line treatments is critical for improving patient outcomes. Three newer agents—fedratinib, momelotinib, and pacritinib—now provide therapeutic alternatives. Navigating the use of JAK inhibitors after ruxolitinib requires evaluating their distinct efficacy fingerprints and safety profiles to match each drug to specific patient phenotypes.

Spleen Volume Reduction and Symptom Control with JAK Inhibitors after Ruxolitinib

Clinical trials show that second-line Janus kinase inhibition can effectively control disease manifestations after ruxolitinib failure. In a pooled analysis of phase 3 data, fedratinib achieved a 35% spleen volume reduction rate of 32.7% at week 24. In contrast, momelotinib demonstrated a spleen response rate of 15.8%, while pacritinib dosed at 200 mg twice daily showed a 21.6% response rate. These data indicate that fedratinib provides potent cytoreductive efficacy for patients requiring substantial spleen debulking.

Furthermore, constitutional symptom control is vital for patient quality of life. The pooled analysis revealed that 32.8% of patients receiving fedratinib achieved at least a 50% reduction in Total Symptom Score at 24 weeks. Similarly, pacritinib achieved a 50% symptom score reduction in 32.4% of patients, whereas momelotinib produced a 25.3% symptom response rate. Therefore, both fedratinib and pacritinib deliver comparable symptom relief, while fedratinib produces the highest rate of spleen volume reduction. Clinicians should evaluate whether spleen debulking or symptom relief is the primary goal before selecting therapy.

Comparing Hematologic Toxicities: Anemia and Thrombocytopenia Risks

Hematologic toxicity represents a central challenge when managing patients after ruxolitinib failure. The pooled safety analysis revealed distinct cytopenia profiles across the three agents. Specifically, fedratinib demonstrated the highest rate of grade 3 or higher anemia at 34.3%. This prominent myelosuppressive effect requires close hematologic monitoring during therapy. In contrast, momelotinib exhibited the lowest incidence of severe anemia at only 8.0%.

Additionally, momelotinib inhibits activin A receptor type 1, which suppresses hepcidin expression and enhances iron availability for erythropoiesis. Consequently, momelotinib frequently improves hemoglobin levels and reduces transfusion dependence in anemic patients. Pacritinib also provides unique hematologic utility because it does not cause severe platelet suppression. In fact, pacritinib is indicated for patients with severe thrombocytopenia having platelet counts below 50,000 per microliter. However, pacritinib carried the highest risk of grade 3 or greater bleeding complications at 11.2%. Clinicians must therefore weigh count preservation against potential bleeding risks in vulnerable patients.

Non-Hematologic Adverse Events and Real-World Safety Signals

In addition to cytopenias, clinicians must monitor distinct non-hematologic toxicities associated with each second-line agent. Fedratinib frequently causes gastrointestinal toxicities, exhibiting an any-grade diarrhea rate of 56.6%. As a result, supportive therapy with antidiarrheals is essential when initiating treatment. Furthermore, fedratinib requires baseline and periodic thiamine monitoring to prevent Wernicke encephalopathy.

Moreover, real-world evidence has expanded our understanding of safety profiles across diverse patient populations. Integrated datasets involving over 1,700 patients showed that drug discontinuation rates due to adverse events were comparable across agents, ranging from 16% to 17%. Notably, real-world evidence from five momelotinib cohorts comprising 580 patients identified specific monitoring priorities. These data revealed estimated glomerular filtration rate decline in 17% to 29% of patients and peripheral neuropathy in 4% to 20% of cases. Therefore, routine surveillance of renal function and comprehensive neurological evaluations must accompany momelotinib therapy. Early detection ensures timely dose adjustments without prematurely terminating therapy.

Phenotype-Driven Selection for Second-Line Myelofibrosis Therapy

Given the diverse pharmacological properties of these agents, treatment selection must follow a personalized, phenotype-driven approach. For patients with massive splenomegaly and preserved blood counts, fedratinib represents an optimal second-line choice. Its robust spleen debulking capacity offers rapid anatomical relief, provided gastrointestinal side effects and thiamine levels are managed.

Conversely, for patients presenting with severe anemia or red blood cell transfusion dependence, momelotinib is the preferred agent. Its dual inhibition of JAK1/2 and ACVR1 directly targets the mechanisms underlying anemia in myelofibrosis. Consequently, momelotinib can improve hemoglobin levels while maintaining adequate spleen and symptom control. For individuals with severe baseline thrombocytopenia, pacritinib serves as the primary therapeutic option. Because it avoids significant platelet suppression, pacritinib enables effective disease control in cytopenic patients. Ultimately, matching the clinical fingerprint of each JAK inhibitor to baseline counts and comorbidities optimizes therapeutic outcomes.

Practical Monitoring and Toxicity Management Strategies

Successful long-term disease control after ruxolitinib failure depends on proactive toxicity mitigation and vigilant patient monitoring. When prescribing fedratinib, clinicians should assess baseline thiamine levels and administer prophylactic thiamine if levels are borderline. Additionally, prescribing pre-emptive antiemetics and loperamide can substantially reduce early treatment discontinuations caused by gastrointestinal distress.

Similarly, clinicians managing patients on momelotinib must establish regular schedules to monitor serum creatinine and renal function. Practitioners should also perform routine sensory assessments to identify peripheral neuropathy before functional decline occurs. When prescribing pacritinib, clinicians must carefully review concurrent anticoagulant medications to minimize bleeding hazards. Furthermore, because treatment discontinuation rates are similar across all agents, temporary dose reductions should precede complete drug cessation. By establishing structured monitoring protocols, multidisciplinary teams can ensure continuous disease control while preserving patient safety.

Frequently Asked Questions

How does spleen volume response compare among fedratinib, momelotinib, and pacritinib?

Pooled phase 3 data show that fedratinib achieves the highest spleen volume reduction of at least 35% at week 24, with a 32.7% response rate. In comparison, pacritinib achieves a 21.6% response rate, and momelotinib produces a 15.8% response rate. Therefore, fedratinib is the most potent cytoreductive choice for splenomegaly, while momelotinib and pacritinib offer tailored benefits for cytopenic patients.

Which adverse events require special monitoring when prescribing momelotinib?

Although momelotinib has the lowest rate of severe anemia at 8.0%, real-world evidence identifies important non-hematologic monitoring targets. Studies show that 17% to 29% of patients experience a decline in glomerular filtration rate, and 4% to 20% develop peripheral neuropathy. Consequently, clinicians must regularly monitor renal function panels and conduct periodic neurological assessments to detect changes early during momelotinib therapy.

When should clinicians consider pacritinib over other second-line options?

Clinicians should prioritize pacritinib for patients presenting with severe baseline thrombocytopenia, particularly platelet counts below 50,000 per microliter. Unlike other Janus kinase inhibitors, pacritinib avoids significant platelet suppression while delivering meaningful symptom reduction in 32.4% of patients. However, because pacritinib carries an 11.2% risk of grade 3 or higher bleeding, clinicians must monitor high-risk patients closely.

Disclaimer: This content is for informational and educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Duminuco A et al. Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real-world evidence. Br J Haematol. 2026 Aug 14. doi: 10.1111/bjh.70754. PMID: 42601824.
2. Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4(5):652-659.
3. Verstovsek S, Gerds AT, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401(10373):269-280.
4. Harrison CN, Schaap N, Vannucchi AM, et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):e317-e324.